Skip to main content
Clinical Trials/ACTRN12622000499785
ACTRN12622000499785
Recruiting
未知

Preventing adverse events during paediatric cancer treatment: A multi-site hybrid randomised controlled trial of catheter lock solutions (The CLOCK trial)

niversity of Queensland0 sites720 target enrollmentMarch 29, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Paediatric Cancer
Sponsor
niversity of Queensland
Enrollment
720
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 29, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Queensland

Eligibility Criteria

Inclusion Criteria

  • Children (\<18 years) with an oncological or malignant haematological condition who have a CVAD in situ (including peripherally inserted central catheters \[PICCs], tunnelled (cuffed or non\-cuffed) \[e.g. Hickman®; Becton Dickinson, US] and totally implanted \[e.g. PORT\-A\-CATH®; Smith Medical, US] will be eligible for inclusion. ; Children (\<18 years) with an oncological or malignant haematological condition who have a CVAD in situ (including peripherally inserted central catheters \[PICCs], tunnelled (cuffed or non\-cuffed) \[e.g. Hickman®; Becton Dickinson, US] and totally implanted \[e.g. PORT\-A\-CATH®; Smith Medical, US] will be eligible for inclusion.

Exclusion Criteria

  • \-End\-of\-life pathway/measures at recruitment
  • \-Pre\-existing coagulopathic condition not related to current diagnosis or treatment (e.g. Haemophilia A and B or other factor deficiency; Immune Thrombocytopenic Purpura (ITP); Von Willebrand’s disease)
  • \-Known allergy to heparin or T\-EDTA
  • ; \-End\-of\-life pathway/measures at recruitment
  • \-Pre\-existing coagulopathic condition not related to current diagnosis or treatment (e.g. Haemophilia A and B or other factor deficiency; Immune Thrombocytopenic Purpura (ITP); Von Willebrand’s disease)
  • \-Known allergy to heparin or T\-EDTA

Outcomes

Primary Outcomes

Not specified

Similar Trials